Axon Therapies, a medtech company focused on heart failure therapies, announced it closed an oversubscribed $32 million Series A funding round, co-led by new investors Earlybird Venture Capital and ...
Axon beat top- and bottom-line estimates, posting 25%-plus revenue growth for the 13th consecutive quarter. The company also raised full-year guidance. Axon is a highly valued stock, but the results ...
Axon Enterprise, Inc. is down 20% after hours. AXON reported a large Q3 EPS miss due to tariffs and increased R&D spending. While short-term headwinds remain, AXON stock represents an attractive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results